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   Antibiotic Resistance: A 21st Century Challenge 
 In 1862, during the battle of Fair Oaks, George Fisk took a bullet to the shoulder. As he 
lay in Washington’s Judiciary Square Hospital, his wound became infected and was soon a 
swollen, puss- and blood-filled mass. The doctor chose not to amputate, and several days later, 
Fisk died from infection.1 In 2006, Sgt. Nathan Reed was escorting a news team through 
Baghdad when his leg was seriously injured by a roadside bomb. While in the hospital, Reed 
contracted an antibiotic resistant infection. The bacterium causing the infection has made the 
short list for dangerous microbes because of the toll it has taken on soldiers in the Middle East. 
Because the risk of trying to fight this particular strain of bacteria is so high, Reed’s doctors 
advised him to choose amputation, which he did rather than risk his life trying to save his limb.2  
 Though the treatment they received was separated by more than one hundred and forty 
years of medical science, both Fisk and Reed faced a life or death decision because of the 
bacterial infection they contracted. Yet there was a time, between the Civil War and now, when 
the majority of infections were easily treated. For a time, Penicillin and other antibiotics made 
life threatening bacterial infections a thing of the past.3 Unfortunately, antimicrobials have been 
misused and overused and this has lead to the growth and spread of bacteria that are resistant to 
antimicrobials. These bacteria do not only affect wounded soldiers. According to the FDA, 
“Disease-causing microbes that have become resistant to drug therapy are an increasing public 
health problem. Tuberculosis, gonorrhea, malaria, and childhood ear infections are just a few of 
the diseases that have become hard to treat with antibiotic drugs." 4  
 Natural selection is easily observed in bacteria because of their short lifespan and 
phenomenal reproductive rate. Antibiotics are extremely useful when combating pathogenic 
bacteria. However, after an antibiotic is used repeatedly, bacteria begin to develop a resistance. 
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This is because the few bacteria with mutations that make them immune to the antibiotic are 
selected for, while those without those mutations are selected against. Therefore, using 
antibiotics increases the likelihood that resistant strains of pathogenic bacteria will survive while 
their counterparts die. As Dr. Lewis said, “In many ways, antibiotic resistance has developed 
along basic Darwinian evolutionary principles. As more and more antibiotics are used, organisms 
that possess genes that make them resistant to antibiotics are more likely to thrive and, therefore, 
are more likely to pass on those genes. Over many years, this pattern has had a significant effect 
on the evolution of infection-causing organisms." 5  
 There are several factors contributing to the increase in antibiotic resistance among 
bacteria, the most prominent of which is doctors’ over-prescription of antibiotics.6 7 Individuals 
are often saved by using antibiotics. However, every time an individual uses an antibiotic, they 
are increasing the chances of the gene pool of infectious bacteria becoming more resistant to that 
antibiotic. Because antibiotics are cheap, and often extremely effective, individuals have 
incentive to use them on a regular basis.8 When people use antibiotics regularly for a long period 
of time, bacteria become so resistant that the antibiotics become close to worthless. This type of 
dilemma is known as a tragedy of the commons. The term tragedy of the commons was coined 
by Garret Hardin to describe a situation in which rational self-interest forces each individual 
actor to exploit a common resource. The result is that everyone’s freedom to act in a self-
interested way forces everyone to race to exploit the resource, eventually bringing the destruction 
of the resource and suffering for all.9 If people only used antibiotics in cases of serious need, 
mankind would reap the benefits.  As it were, the welfare of the human race is of little 
significance to individuals who know using antibiotics will give them relief from their immediate 
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suffering. The incentive is even smaller when an individual knows that others are also overusing 
the same antibiotic, and it will eventually become ineffective.  
  The gene pool of infectious bacteria should be considered a common-pool resource. 
Over two-hundred and fifty organizations with members from fifty different countries have 
signed a treaty which recognizes the global gene pool as a common pool resource.10 The gene 
pool of infectious bacteria has the characteristics of a common pool resource which, as defined 
by Ostrom and Ostrom, are resources that are hard to exclude people from and when used, 
become more difficult for another to use.11 The gene pool of infectious bacteria has low 
excludability because it is hard to keep people from using antibiotics. Antibiotics and the 
infectious bacteria gene pool posses the quality of subtractability because one person’s use of an 
antibiotic increases the chance that later users will find antibiotics less effective. While the 
supply of antibiotics is not noticeably limited, the number of times antibiotics can be used 
effectively is. 
 When examining a common pool resource, it is critical to have a proper understanding of 
the elements that affect that resource.12 This paper will examine several of the elements 
identified in the Institution Design and Analysis (IAD) framework, as discussed by Ostrom. 
Ostrom and colleagues say the IAD framework should be used to examine common-pool 
resources. IAD examines each aspect of an action situation by categorizing the different elements 
and then examining how they interact. This paper will take an institutional approach by focusing 
on the rules humans can develop to address the threat of spreading antibiotic resistance. The 
question this paper seeks to answer is "What is the proper institutional response to the overuse of 
antibiotics and the threat of spreading antibiotic resistance?" 
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 This paper will treat the lack of antibiotic resistance among the gene pool of infectious 
bacteria as a common pool resource and examine the institutions designed to protect this 
resource through the perspectives provided by common pool resource theory. This paper will 
examine the United States and the Netherlands, two cases which support the theory surrounding 
the governance of common pool resources. Finally, after using governance of the common’s 
theory and the lessons learned from different national level approaches to combating antibiotic 
resistance, this paper will make some recommendations for institutional change in countries like 
the U.S., who are struggling to keep antibiotic resistance under control.  
 
A Short History of Antimicrobial Resistance 
 In the 1940’s, Penicillin changed the world by turning life-threatening infections into 
easily treated inconveniences.13 14 During World War II, the Allies had an unprecedented low 
amount of deaths due to disease because of this new technology.15 The United States and Britain 
were so impressed with the results of Penicillin that by D-Day the two countries were producing 
a billion units per month. 16 Penicillin’s unprecedented effectiveness combined with the ease with 
which it can be produced has lead to its wide spread use.17 Unfortunately, bacteria have been 
able to adapt. By 1942, pathogenic strains of bacteria began showing signs of resistance to 
penicillin and now penicillin is completely ineffective against many of the newer, mutated strains 
of bacteria.18 Penicillin is still the most widely used antibiotic, 19 however, its possible uses are 
continually narrowing because more and more strains of penicillin resistant bacteria are 
developing. 20 By 1961, Patricia Jevons reported that only two percent of all remaining strains of 
S. aureus, a common pathogenic bacterium in England, could be treated with Penicillin.21 
Because of the extensive use of Penicillin in England, ninety-eight percent of staphylococcus 
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aureas (S. aureas) strains were already completely immune to what was once a potent antibiotic. 
22 The response of the medical and scientific communities was to develop new antibiotics, such 
as methicillin, one of the first semi-synthetic antibiotics that could kill penicillin resistant 
bacteria.23 24 However, S. aureas has now developed several hardy, methicillin-resistant strains. 
In 2004, it was reported that in the U.S., sixty-four percent of staph bacteria were resistant to 
methicillin.25 These methicillin resistant S. aureas (MRSA) often posses immunity to multiple 
antimicrobials. 26 Patients who contract MRSA are four times more likely to die than other 
patients.27 In order to effectively treat these bacteria, more potent antibiotics have been 
developed.28 Extremely potent antibiotics are able to kill most resistant bacteria, but they often 
cause harmful side effects. Vancomycin is a newer antibiotic that is used to treat infections 
resistant to methicillin,29 however, it is so potent that doctors prefer to use it only as a final 
resort, when all else fails.30 Now there are new strains of infectious bacteria that show complete 
resistance to Vancomycin.31 What is worse is that some of these bacteria seem to be resistant to 
everything and are thus termed “superbugs." 32 
 The cycle repeats itself. An antibiotic is developed and then the bacteria mutate and form 
a resistance so that another antibiotics must be developed. John Powers, a lead medical officer 
and researcher for the National Institute of Allergy and Infectious Diseases, describes each 
antibiotic as a “tank of gas” that has a limited number of uses, and claims: “When it runs out, it 
runs out." 33 Unfortunately, it is becoming very hard and very costly to develop new antibiotics 
that are effective against the increasingly resistant strains of bacteria.34 Therefore, the supply of 
new antibiotics is limited.35 In the past, physicians were able to defend the careless overuse of 
antibiotics by pointing to the continuous stream of new, effective antibiotics.36 This cannot 
continue because the supply of new, effective antibiotics, and the rate at which they are being 
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produced, is quickly diminishing.37 If the number of resistant bacteria continues to grow, we may 
find ourselves fighting infections from a position similar to the days before penicillin.38  
 The development of antibiotic resistant bacteria can be avoided, or at least, substantially 
slowed.39 These bacteria are most likely to develop when antibiotics are used liberally and 
irresponsibly.40 For example, many of these bacteria are developing as a result of feeding 
antibiotics to animals.41 Farmers find antibiotics a cheap and effective way to keep their animals 
free of infection.42 The problem is that after extensive use, strains of bacteria that are resistant to 
the antibiotics begin to emerge.43 These bacteria enter the soil, air, or water, and eventually come 
in contact with humans. Some scientists claim that “Keeping antibiotics out of animal feed in the 
first place is the best way to limit the development of antibiotic resistance and keep antibiotics 
working in humans." 44  
 Another way antibiotics are irresponsibly consumed is when people take them as 
preventatives or use them without proper diagnosis (Lowy 2003).45 Many people take antibiotics 
when they have a common cold  in case their symptoms are the result of an infection.46 The 
result is that they are often doing nothing to combat their cold and they are increasing the 
likelihood of antibiotic resistant bacteria. The same thing happens when doctors misdiagnose a 
symptom as being the result of an antibiotic treatable bacterium when the patient is really 
suffering from something else.47 Finally, antibiotic resistant bacteria occur quite often in cases 
where a patient suffering from a bacterial infection does not take the  full prescription of 
antibiotics.48 The result is a long touch and go battle with the bacteria which gives the bacteria 
time to develop a resistance to the antibiotic being taken.49 There is always hope that new, 
stronger antibiotics will be developed or new methods for combating infection will be 
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discovered. However, as these technologies are pursued, more must also be done to stop the 
continual spread of antibiotic resistance. 
 
Common Pool Resource Theory  
 Charlotte Hess has studied commons for over eighteen years.50 In her paper, "Mapping 
the New Commons," she identifies six "triggers" which lead people to identify a resource as a 
commons. One of these identifying triggers is the occurrence of a tragedy of the commons.51 
Hess says that there is a need to quickly identify threatened commons before they are depleted or 
destroyed. 52 Hess quotes Levine, who said, "People must exhibit mutual trust, habits and skills 
of collaboration, and public spirit in order to sustain such a common pool resource against the 
tendency of individuals to abuse it." 53 
 Over the last twenty-five years, there has been tremendous growth in the knowledge and 
theory surrounding common-pool resources.54 There is still much to be discovered in this new 
field, however, the existing theory already has the ability to lend considerable wisdom and 
insight to those attempting to preserve a common-pool resource.55Social interactions surrounding 
common-pool resources do not always degenerate into a tragedy of the commons.56 Tragedy of 
the commons scenarios most often occur when the users of a common-pool resource have 
difficulty communicating and interacting in such a way as to develop trust.57  
 Peter Kollock, a professor of sociology at U.C., defines "social dilemma" as a scenario in 
which "individually reasonable behavior leads to a situation in which everyone is worse off."58 
Kollock describes the social dilemma in a tragedy of the commons as a "social trap" in which 
each individual can either choose immediate benefit that incurs future hardship on all, or forego 
immediate benefit so as not to cause hardship on everyone. Kollock says that individuals often 
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have incentive to choose the immediate benefit, and when enough individuals choose this, the 
common pool resource is depleted.59 
 Kollock provides an example scenario in which there is a forest that people are able to 
harvest trees from. Every time a person takes trees from this forest, there are fewer trees for 
everyone else to harvest. However, the benefit to the individual of having lumber is much greater 
than the cost of not being able to harvest these trees again. Harvesting trees makes even more 
sense for the individual who considers that if he or she does not harvest them, someone else will. 
Unfortunately, when all the individuals follow this logical path and harvest the trees, the forest is 
soon depleted.60 What these individuals need to do is come together and create an institution (i.e. 
rules that restrict individuals from overharvesting and thus prevent the resource from being 
depleted). Kollock notes that one of the most important factors for those creating the rules to 
consider is the rate at which the resource replenishes itself.61 This knowledge is essential when 
trying to determine the maximum sustainable rate at which the community can use the resource.  
 Finding the elements which make up a successful common-pool resource governing 
institution has been the aim of a considerable portion of the research surrounding common-pool 
resources. Kollock's research lead him to conclude that frequent communication and easy access 
to information were both critical components of successful institutions. 62 Eleanor Ostrom, a 
leader in the study of common-pool resources, who was awarded the 2009 Nobel Prize in 
Economic Science for her work, agrees with Kollock. When she examined institutions that were 
developed by groundwater consumers in the L.A. basin to preserve sustainable levels of 
groundwater, she concluded that it was of paramount importance that those working within the 
institution know each other's actions and be able to ascertain the general level of compliance 
with the rules. Ostrom found that when everyone's use of groundwater was metered, published, 
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and distributed, the threatened sanctions for misbehavior never needed to be enacted . If one 
person overused water, everyone learned of it, and therefore, individuals were very quick to 
correct their misbehavior.63 When individuals have enough information to determine that others 
are obeying the rules outlined by the institution, the institution gains credibility, and voluntary 
compliance is more likely.64 
 In “Governing the Commons: The evolution of institutions for collective action,” Elinor 
Ostrom examines four common-pool resources which have been successfully governed for an 
extended period of time without external assistance. These four common-pool resources are land 
in the Swiss mountains, the forests in Japan, the water in arid Spain, and irrigation systems in the 
Philippines. In the Swiss mountains, communities used a system which involved both private 
land for agriculture and communal land for grazing and wood gathering. In Japan, forests and 
land were extremely scarce and thus crops were harvested and shared by the community. In 
Spain, water was extremely scarce and the supply was very unpredictable. However, 
communities found ways of agreeing upon how to allocate the water and closely self-regulate 
that usage. In the Philippines, a set of rules was devised for determining the amount each should 
contribute  to the maintenance of the irrigation systems. This system was carefully created in a 
way which was fair so that those who put effort into the system were able to reap a proportional 
reward. 65   
 Ostrom identifies common characteristics among the successfully managed commons she 
discusses. They had clearly defined boundaries. They had rules which were specifically tailored 
for that resource and took into account its abundance, reliability, frequency, sustainability, and 
other characteristics. The institution could be changed by the those it regulated. The use of the 
resource was carefully monitored, and the systems for monitoring were part of the institution of 
Pilch 11 
 
 
governance. The institution was enforced by sanctions that took context into consideration, 
became greater after repeated violations, and were proportional to the grievances. The institution 
had a system for resolving conflict. The community’s institution was recognized as legitimate by 
outsiders. Finally, in the common-pool resources that were integrated into a larger economical 
system, the different aspects of the governing institution were organized into “nested 
enterprises.”66 By identifying the characteristics common to successful institutions, Ostrom gives 
guidance to those hoping to create new, successful, and long-lasting institutions for the 
preservation of endangered common-pool resources.  
 Stern et, al. offer complimentary advice in their work "Knowledge and Questions after 15 
years of research."67 They claim that when crafting an institution to protect a common-pool 
resource, it is important to have an understanding of the actors involved and the incentives they 
face. 68 It is best when those who use the resource are also those who are monitoring resource use 
and enforcing rules. Stern et. al. found that the success of an institution is often connected to 
participants ability to create the rules and sanction inappropriate actions. Stern et. al, also 
concluded, in agreement with Ostrom and Kollock, that systems of monitoring are essential to 
the preservation of a common pool resource.69 
 
Case Studies 
 Stern et, al. advocate case studies as a method for mapping and examining new 
commons.70 They say that, "In such frontier research areas, in-depth observation is needed to 
uncover phenomena or variables that would be missed if researchers only looked at variables 
known to be important."71 They also note that case studies can be used to test the application of 
theories or to develop new theories. 
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 The purpose of this paper is to formulate and then support recommendations for 
institutional change in countries which are struggling with a tragedy of the commons in the realm 
of antibiotic resistance. By examining different national level interactions with antibiotic 
resistant disease, one can search for policies which have worked as well as policies which have 
failed. One can also use these case studies to test common-pool resource theory and its 
application to antibiotic resistance. The nation-state is a complex collection of people, culture, 
geographical features, and institutions. When studying two or more nations, it is hard to draw 
direct comparisons. It can be even more challenging to determine to what extent each factor 
considered caused the observed results. Therefore, this paper will use the case study method, 
which allows for a detailed description of different cases, a discussion of the results achieved in 
each case, and a cross-case comparison.  
 The following case studies will examine antimicrobial resistance at the nation-state level, 
because this is currently the optimal level for the implementation of institutions designed to 
combat antimicrobial resistance. Antimicrobial resistance does not respect political boundaries, 
and therefore, the failure of one hospital, city, or state can negatively affect its neighbors. 
Though one state may do an excellent job rationing antibiotics and eliminating resistance, its 
hard work can be undermined by an infection which spreads from another state. 72 The same can 
happen across national borders and so ideally, a global level institution could be used to enforce 
the rational use of antibiotics. Unfortunately, international institutions lack sanctioning power, 
and there is currently no international level institution that has the ability to provide proper 
incentives and sanctions. Therefore, collective action crafted to lessen the impact which 
antimicrobial resistance has upon humans should be directed from the national level. 
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 The following case studies will examine the United States and the Netherlands. Two 
developed, western nations that have adopted different approaches to controlling the spread of 
antibiotic resistance.  
 
United States 
 The United States is a nation that privileges freedom and individual choice. The people of 
the United States have historically favored individualism over collectivism, unlike the societies 
of Japan, China, and Europe.73 Individualism places importance upon the individual rather than 
the collective. Individualism stresses virtues like independence and self sufficiency. The political 
doctrine of individualism holds that "The interests of the individual are or ought to be ethically 
paramount." 74 A free market is a natural component of an individualistic society.75 The market 
for antibiotics in the U.S. is a relatively free market, though patients must have a prescription in 
order to purchase them.  
 In most cases, the United States free market approach has provided abundant incentive 
for pharmaceutical companies to develop new drugs. In 2002, the companies based in the United 
States spent 15 billion dollars on research and development for medicine.76 Though the 
investment is huge, the financial return has been even larger and the social benefit of the 
investment has been an increase in new, innovative and efficient treatments. 77 Twenty percent of 
what American's spend on new medicine is funneled back into medical research and this is 
funding an ever-increasing amount of biomedical innovation. 78 In 2002, eighty-nine new 
medicines were introduced into the U.S. market, but for the first time in several years, not a 
single new antibiotic was approved. In fact, as demonstrated by figure 1, the number of new 
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antibiotics approved by the FDA has continued to decline.79 
 
Infectious Diseases Society of America (2010). Retrieved from <http://www.idsociety.org/badbugsnodrugs.html> 
 Figure 1 shows the number of new antibacterial agents approved by the FDA per five 
year period. The figure shows that from 1983 to 1987, the FDA approved sixteen new 
antibacterials. The figure also shows that from 2003 to 2007, the FDA only approved four new 
antibacterials. Over that twenty-five year period, discovery and approval of new antibacterials 
decreased seventy-five percent. In the last two years, 2008 and 2009, only one new antibacterial 
has been approved.  
 The free market is not providing enough incentive for research and development of new 
antibiotics. 80 In other words the large drug companies which specialize in the research and 
development of new medicinal drugs have found that the development of new antibiotics is not 
as profitable as the development of drugs used to treat chronic illness and other diseases. Patients 
only use antibiotics for a week or two, while a patient with a chronic disease will likely be 
purchasing pharmaceutical drugs for the rest of their life.81 Antibiotic research is also less 
profitable because in the global market, doctors are beginning to hold new antibiotics in reserve 
to be saved for the most resistant infections. 82 Because this practice is beginning to become more 
popular, pharmaceutical companies fear that a new antibiotic may not be used frequently after its 
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development and therefore, it will take longer to collect return on their investment. 83 Finally, 
when asked what could be done to encourage the research and development of new antibiotics, 
pharmaceutical and biotechnology companies have stated that the FDA's requirements for drug 
development change too quickly and greatly increase the cost of research and development. 84 
These companies have continually requested a streamlining as well as a standardization of the 
FDA's drug approval policies.85 Until these disincentives are addressed or new incentives are 
given, it is reasonable to assume that fewer and fewer antibiotics will be developed. In 1990, half 
of big medical research and development companies in the U.S. cut or significantly reduced their 
antibiotic development division. 86 Then, between 2000 and 2004, even more cuts were made by 
the companies who had continued to research new antibiotics. 87 It takes about ten years for an 
antibiotic to be discovered, tested, approved, and produced. 88 The considerable downturn in 
funds being invested now suggests that the next ten years will see the introduction of even fewer 
new antibiotics. 
 For decades, antimicrobial resistance has spread quickly in the United States.89 This 
continual increase can be seen in Figure 2. This figure is a graph published by the Center for 
Disease Control (CDC) , a government agency that has compiled data which shows the steady 
increase in antibiotic resistance. The graph shows the percentage of three common bacterial 
infections that are resistant to an antibiotic commonly used to treat them. For example, the 
uppermost line shows the percentage of staph infections, caused by the bacteria staphylococcus 
aureus, that were resistant to methicillin in a given year. Enterococci are bacterium known to 
cause urinary tract infections and meningitis.90 As one can see from the figure, until the late 
1980's, all cases could be treated with the antibiotic vancomycin, but recently, strains of resistant 
enterococci, known as vancomycin resistant enterococci (VRE), have been found. Figure 2 
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shows that in the year 2000, a little more than twenty percent of enterococci infections were 
resistant to vancomycin. From the graph we can also see that after the year 2000, levels of 
methicillin resistance have increased to more than fifty-five percent. This means that more than 
half of all staph infections are resistant to treatment from methicillin, which was once the most 
effective antibiotic available in cases of staph infection. 91 
  
Infectious Diseases Society of America (2010). Retrieved from <http://www.idsociety.org/badbugsnodrugs.html> 
 Until recently, the spread of antibiotic resistance was not considered a serious threat 
because experts and government officials expected new antimicrobials to be developed as 
quickly as old drugs became ineffective.92 Indeed, if antimicrobial resistance stayed at a 
manageable level and new drugs were continually put on the market, antimicrobial resistance 
would not become a serious threat. Unfortunately, the Infectious Disease Society of America 
(IDSA) reports that the supply of new and approved antibiotics has been steadily declining. 93 
The IDSA is a group of concerned doctors, medical microbiologists, and public health workers. 
The association is concerned by the lack of new antibiotics being developed to treat new levels 
of antibiotic resistant infections.94 The association reports that this year, more than two million 
Americans will contract a bacterial infection in a hospital and now, close to seventy percent of 
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these infections will be resistant to antibiotics. 95 Because of the prevalence of resistance, ninety 
thousand of these patients will die as a result of their infections. 96 If nothing is done, the decade 
to come will be even worse.97 
 It is possible that government officials hold pharmaceutical companies responsible for the 
shortage of antibiotics and therefore, are reluctant to offer them incentives to fix a problem they 
allegedly created. However, the IDSA considers the shortage of new drugs a societal problem 
and one that requires collective action to overcome. The IDSA argues that large research and 
development corporations cannot be blamed for the current shortage of antibiotics. 
Pharmaceutical companies have a legal responsibility to pursue profit, not the public good. The 
IDSA argument is supported by U.S. court rulings which allowed shareholders to sue corporate 
directors because the director was using the shareholders' funds to pursue public health interests 
rather than high investment yields. 98 
 Though the supply of new antibiotics is dwindling, the United States government has not 
placed any considerable restrictions upon antibiotic use. For a developed nation, the U.S. has an 
unusually large division between public-health agencies and individual care providers. 99 Public-
health agencies, like the FDA (Food and Drug Administration) and CDC (Center for Disease 
Control) are better positioned to use collective rationale. They advocate the preservation and 
conservative use of antibiotics. Most doctors know that antibiotic use contributes to antibiotic 
resistance, but many are reluctant to reduce their use of antibiotics. 100 Congress has not granted 
the FDA or the CDC the power to regulate antibiotic use.101 
 The Center for Disease Control conducts surveys about antibiotic use within the United 
States as well as studies designed to determine antibiotic resistance levels among infectious 
disease. The Public Health Service Act of 1994 gave the CDC the power to quarantine those it 
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suspects of having an infectious disease.102 The CDC has not received the funding necessary to 
create and enforce rules regarding the hospital's quarantine of patients suspected of having an 
antibiotic resistant infection. 103 Legislation regarding isolation of patients known to be infected 
and the quarantine of those suspected of being infected is handled at the state level and there is a 
great disparity between the level of quarantine and isolation mandated by different states.104  The 
CDC has not received funding sufficient to monitor antibiotic use. However, the CDC has 
published statements warning that serious action and commitment will be required when the U.S. 
decides to properly address the spread of antibiotic resistance.105 Though it faces a lack of 
funding, the CDC has taken steps to prevent antibiotic resistance. 106 It has worked with other 
agencies as well as action groups to spread a public awareness campaign that outlines the 
problem of antibiotic resistance and encourages people not to misuse antibiotics. The CDC has 
also participated in efforts to develop an action plan that outlines the steps the United States 
should take when the federal government begins legislating institutional changes for the purpose 
of combating antimicrobial resistance. 107  
 The lack of federal guidance combined with the inconsistency of state regulations has 
created a great disparity between hospital practices. Dr. Alan Zillich and colleagues conducted a 
survey of infection control staff in U.S. hospitals in an attempt to determine the level to which 
U.S. hospitals regulate antibiotic use. 108 The survey found that fifty-nine percent of surveyed 
hospitals followed guidelines for antibiotic use during surgeries. About half of the U.S. hospitals 
required physicians to get approval before using extremely potent antibiotics. Less than half of 
U.S. hospitals provided physicians with information about each other's antibiotic use. About one 
fourth of the surveyed physicians reported that their hospital used some sort of automated 
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software to help physicians prescribe the correct antibiotic and monitor antibiotic 
prescriptions.109  
 In his Congressional Quarterly article, Fighting Superbugs, Clemmitt reports that 
antibiotics are overprescribed in the U.S.. Clemmitt claims that this is due in part to the fact that 
patients often consider antibiotics to be a miracle drug and therefore, when they feel ill they 
demand antibiotics from their physician. Clemmitt links this irrational demand to drug 
companies in the U.S. that use aggressive advertising campaigns to increase demand for their 
products.110 Doctors have monetary incentives to keep their patients happy. It's also very easy for 
a doctor to give their patient antibiotics, while it is considerably harder for a doctor to diagnose a 
patient’s problem and then convince the patient they don't need antibiotics. Clemmitt cites 
studies which have shown that doctors are much more likely to prescribe antibiotics when they 
feel pressure from their patients to do so. He also cites studies which discovered that in the U.S., 
as many as nineteen out of twenty prescriptions for antibiotics are unnecessary and could be 
prevented by proper diagnosis and appropriate treatment. The result of all these unnecessary 
prescriptions is a flood of antibiotics being released into our hospitals and communities, this 
places extraordinary selective pressure on bacteria communities and the result is a continual 
increase in antibiotic resistance. 111  
 Antibiotics are overprescribed in the U.S. but despite the unnecessary prescriptions, still 
more antibiotics are given to animals. It is estimated that seventy percent of antibiotics used in 
the United States are used on domestic animals.112 A considerable number of those antibiotics 
are similar to those given to humans and therefore, some health workers worry that we are 
putting selective pressure on bacteria to become resistant to antibiotics even before the infections 
spread to people. 113 It was this fear which lead the European Union to ban the use of antibiotics 
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as growth promoters in domestic animals if those antibiotics were similar to those prescribed to 
humans. 114 However, in the U.S., a considerable amount of controversy has developed around 
this type of legislation. Some have argued that the scientific support for the connection between 
antibiotic use in animals and antibiotic resistant infections in humans is too weak to warrant a 
ban.115 They claim that the negative impacts of such legislation, for example, higher meat prices, 
will not justify any decrease in antibiotic resistance. 116 However, there are a number of scientists 
who cannot accept the idea that putting twenty-five million pounds of antibiotics into our 
livestock every year has little negative effect upon the local population of bacteria.117 During the 
last decade, Congress has proposed legislation similar to that passed by the E.U. Those 
supporting this legislation cite studies which have identified three infections, Salmonella, 
Campylobacter, and E. coli, which physicians and veterinarians say are connected to antibiotic 
use among animals. 118 They also cite some worrisome reports by the United States Geological 
Survey which found traces of antibiotics in almost half of the U.S. streams surveyed. 119 Despite 
the support for this legislation, the United States has yet to pass legislation which restricts 
antibiotic use among animals and farmers are still able to give their animals large doses of 
antibiotics without a permit or prescription. 120 
 Organizations dedicated to combating antimicrobial resistance have been frustrated in 
their efforts to persuade Congress to pass regulations aimed at preserving the effectiveness of 
antibiotics.121 Since 2004, IDSA has been lobbying Congress to enact stricter regulations of 
antibiotic use. A few members of Congress have listened to the IDSA and introduced legislation 
which would enact the policy changes the IDSA recommends. However, the majority of 
Congress has been occupied with other issues and therefore, the legislation proposed by the 
IDSA has been ignored.122 
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The Netherlands 
 The Netherlands is a physically small nation which covers about 41,526 sq km. It is 
comparable in size to the state of Maine. However, it's population of more than fifteen million 
makes it one of the world's most densely populated countries.123 The Netherlands takes a 
collectivist approach to the provision of health care. Everyone has access to healthcare, and the 
government subsidizes a considerable amount of the cost. 124 As a member of the EU, the 
Netherlands participates in a ban on giving certain antibiotics to animals. The antibiotics banned 
are antibiotics which physicians and microbiologists feared would contribute to a resistance that 
was transferable to humans.125 The legal system of the Netherlands provides for the protection of 
physicians' independence.126 However, the government organizations which monitor health care 
in the Netherlands have the authority to set hospital policy and demand physicians' 
compliance.127 Hospitals in the Netherlands have a legal obligation to prevent the spread of 
infection between patients.128 Hospitals are also required to participate in the national campaign 
to fight the spread of antibiotic resistant infection.129 
 The Netherlands has exceptionally low levels of antibiotic resistance. 130 For example, the 
incidence of MRSA colonization in Netherland's hospitals is roughly one percent, while 
surrounding countries see incidence levels between ten and forty percent.131 The Netherland's 
success is credited to a national policy of restricting antibiotic prescriptions and mandating 
aggressive quarantine practices.132 Much of the Netherland's search and destroy campaign is 
directed against MRSA (Methicillin Resistant Staphylococcus Aureus), an antibiotic resistant 
infection that is often resistant to multiple antimicrobial drugs and therefore threatens hospitals 
across the world.133 
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 In a report which outlined the Netherlands model for infection control, A. Voss and J. 
A.J. W. Kluytina describe three government agencies which coordinate the country's efforts to 
minimize bacterial infection. These agencies are the Dutch Health Care Council, the National 
Institute of Public Health and  Environmental Protection (RIVM) and the Working Party on 
Infection Control (SWAB). 134 The Dutch Health Care Council requires every hospital to employ 
a committee of infection control specialists. This committee is composed of infection control 
nurses who work under the guidance of medical microbiologists. These committees work within 
the hospital administration to ensure that the national guidelines for infection control are 
implemented. The committees also monitor antibiotic prescriptions and the spread of infection, 
work with physicians on cases of exceptionally life threatening infections, and assist with the 
disinfection of hospital rooms. The National Institute of Public Health and Environmental 
Protection collects data from these committees and compiles it to create a national report which 
describes national levels of infection, antibiotic use, and antibiotic resistance. The Working Party 
on Infection Control compiles literature on infection control, publishes the national guidelines 
for infection control, and provides a database of knowledge for physicians and infection control 
specialists. 135 
 Hospital compliance with the national guidelines has been the key to the Netherlands 
success.136 In a recent survey of ninety-two hospitals in the Netherlands, all were found to have a 
committee of infection control specialists. All but three of the hospitals were using a 
computerized tool, a formulary to determine how and when antibiotics should be prescribed. 
Many of the hospitals were also conducting educational meetings on antibiotic use and giving 
doctors feedback as to their success in preventing antibiotic resistance.137 In 2008, the National 
Institute of Public Health and  Environmental Protection (RIVM) and the Working Party on 
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Infection Control Strict reported that levels of antibiotic use had only marginally increased since 
the early 1990s.  The report found the levels of resistance increased in proportion to the 
increasing use of the respective antibiotic. The report concluded that antibiotic use and 
antimicrobial resistance were both at sustainable levels138. Adherence to national guidelines has 
created a uniformity among infection control practices in hospitals within the Netherlands. The 
uniformity of  infection control in the Netherlands allows for a detailed discussion of how a 
patient will be treated, that remains fairly accurate regardless of the hospital into which the 
patient is admitted.  
 Vos, et. al give a detailed description of how patients exhibiting Methicillin resistance are 
quarantined in the Netherlands. Upon admission to a Netherland's hospital, patients are 
categorized into three groups: those known to be carrying MRSA, those with a higher than 
normal probability of carrying MRSA, and those whose characteristics do not suggest a  higher 
than normal probability of carrying MRSA. 139 A patient is placed in the first category once a test 
has confirmed that they have MRSA. Patients are placed in the second category if they have 
been, "Treated in a foreign healthcare institution; transferred from a medical center with an 
outbreak of MRSA not brought under control; had contact with an individual with proven MRSA 
colonization or infection; [or if they are] an adopted child from abroad." 140 A patient who is 
known to have MRSA is subjected to strict isolation.141 A patient in the second category, who is 
suspected of having MRSA, is placed into quarantine until two different tests are completed. 142 
If one of the tests returns positive, the patient becomes a confirmed MRSA carrier and is moved 
into category one and strict isolation, but if both of the tests return negative, the patient can be 
removed from quarantine.143 Patients who fall into the third category are not quarantined upon 
admission.  
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 When a patient is placed into strict isolation, they are put in single bed room. When 
possible, they are put in a room that has negative air pressure and an anteroom. 144 This means 
that the anteroom has lower air pressure than the hospital ward, and the patient's room has lower 
air pressure than the anteroom. Therefore, whenever a door is opened, air travels towards the 
patient's room, not away from it. This prevents the spread of airborne bacteria. The patient is 
assigned to a doctor and an infection control nurse. 145 In life threatening cases, the patient might 
also be placed under the direct care of one of the hospital's medical microbiologists.146 Doctors 
and nurses attending the patient wear masks, gowns, gloves, and caps. After attending the patient 
but before leaving the anteroom, hospital staff must be thoroughly disinfected. Cultures are taken 
from the patients infection so that the bacteria can be identified. 147 Tests which reveal the 
genetic strain of bacteria are performed. 148 These tests are performed by an infection control 
nurse or microbiologist. Using these tests, doctors and infection control staff can determine the 
exact genetic makeup of each infection and then trace that infection to the hospital or community 
in which it originated. Sixty to eighty percent of MRSA infections are linked to hospitals outside 
of the Netherlands. 149 These tests also allow doctors to determine which antibiotics will 
successfully kill the bacteria, and which antibiotics the bacteria has resistance to. 150 The doctor 
can then consult a formulary to determine which of the available antibiotics should be used. 151 
The formularies are designed to prevent overuse and misdiagnosis of antibiotics so that the local 
community of infectious bacteria will not acquire resistance at a threatening rate. The 
formularies are also designed to prevent important antibiotics from being overused. While in 
isolation, patients are washed with disinfectant daily and given the formula prescribed regimen 
of antibiotics.152Patients are held in strict isolation until six successive tests for MRSA have 
negative results. 153  
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 When it is discovered that a hospital patient who is not in quarantine has contracted 
MRSA, it is assumed that the infection has spread throughout the entire ward.154 The entire ward 
is placed into temporary lockdown until every patient and staff member in the ward has been 
tested. 155 
 There is a considerable upfront cost to pursuing such a zealous search and destroy policy. 
Some might assume that such a radical approach to combating antibiotic resistance does not 
make fiscal sense. An extensive cost-benefit analysis was conducted by Van Rijen and 
Kluytmans, two Dutch infectious disease scientists. 156 The study was performed in a Netherlands 
hospital, Amphia, and it revealed that the policy saved the hospital both lives and money.157 In 
this study, Van Rijen and Kluytmans determined that the policy costs the Amphia hospital 
215,559 euro per year. The majority of these expenses were the wages for the infection control 
committee. It was predicted that if the policy was not pursued, the hospital would pay 427,356 
euro per year combating additional cases of MRSA. An average of ten patients per year die at 
Amphia because of antibiotic resistant infection. It was estimated that between eighteen and 
twenty seven patients would die each year if the policy was not pursued. Therefore, Van Rijen 
and Kluytmans claim that the hospital saved between eight and seventeen lives as well as 
roughly two hundred thousand euro per year. 158 Since sixty to eighty percent of MRSA cases in 
Dutch hospitals occur in patients who have been transferred from a hospital outside of the 
Netherlands, the cost of the Netherland's search and destroy policy would decrease considerably 
if all of the neighboring countries were to adopt a similar policy.  
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A Comparison Between The Netherlands and The United States 
 There are challenges to performing a cross case comparison between the United States' 
treatment of infectious disease and the Netherlands' treatment of infectious disease. In the U.S., 
there is such diversity between hospital practices that it is difficult to generalize and view the 
situation as a whole. In the Netherlands, strict adherence to national guidelines has created a 
uniformity among infection control practices. The uniformity of the infection control in the 
Netherlands allows for a detailed discussion of how infection is fought that remains fairly 
accurate regardless of the hospital. This type of discussion is not possible when examining the 
U.S. Other differences which complicate comparisons of national level policy include 
differences in society, population size, and geographical size.  
 Despite these difficulties, it easy to determine that United States and the Netherlands 
have significantly different approaches to fighting infectious bacteria. The Netherlands has 
adopted many of the design features which common-pool resource theory suggests are necessary 
for the successful governance of a commons. In the United States, the conditions are similar to 
those described around the occurrence of a tragedy of the commons. Therefore, it should not be 
surprising that the spread of antibiotic resistance is under control in the Netherlands, while 
antibiotic resistance is rapidly increasing in the United States.  
 In the United States, doctors have incentive to do what their patient wants, but they are 
rarely held accountable for many of the negative side effects the over prescription or 
misprescription of antibiotics has upon their community. In the Netherlands, doctors have 
incentive to do what is best for their patient, but they are often required to consult a formulary or 
medical microbiologist before prescribing antibiotics, and they are held responsible for their 
prescriptions. Medical microbiologists are further removed from individual patients. They are 
Pilch 27 
 
 
responsible for the health of their entire hospital. Therefore, they are better positioned to 
prescribe antibiotics in ways that are more rational for their community.  
 The Netherlands and the United States have very different levels of monitoring. In the 
Netherlands, every prescription is tracked. Hospital staff can access information regarding every 
doctor's prescription of antibiotics. Every hospital has an infection control committee which 
compiles data about the hospital's use of antibiotics and the hospital's population of infectious 
bacteria. This information is sent to the National Institute of Public Health and Environmental 
Protection which compiles this information into a yearly report that is available to everyone. The 
United States has no comparison. The Center for Disease Control conducts surveys about 
antibiotic use within the United States as well as studies designed to determine antibiotic 
resistance levels among infectious disease. However, these are surveys, not censuses, and the 
information is not used to hold hospitals to any standard. 
 Hospitals in the Netherlands have a much better understanding of how well other 
hospitals are controlling the spread of antibiotic resistance. One reason for this is the annual 
national report that documents antibiotic use and the prevalence of antibiotic resistance. Another 
reason is the tests performed by infection control specialists upon cases of antibiotic resistant 
infection. Because these tests are able to determine the exact genetic makeup of each infection 
and then trace that infection to the hospital or community in which it originated, they provide a 
level of peer-to-peer monitoring. Hospital staff know if the infection in their ward came from a 
neighboring hospital. They also know that if they lose control of an infection and the infection 
spreads to other hospitals, the other hospitals will hold them accountable. This information helps 
the staff of successful hospitals build trust between each other. This information also puts 
significant positive peer-pressure on irresponsible hospitals, giving them incentive to improve.  
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 The combination of information on antibiotic use available in the Netherlands provides a 
level of transparency similar to that described by Ostrom when she examined successful water 
use governance institutions. According to her theory, transparency should provide hospital staff 
in the Netherlands with enough information to realize that collective action is working and the 
Dutch health institutions are keeping antibiotic use at appropriate levels. When an individual can 
see successful results coming from their participation in collective action, this, combined with 
the fear of being caught breaking rules helps to motivate compliance. On the other hand, the lack 
of similar transparency in the U.S. creates a situation in which doctors have little fear of being 
caught inappropriately prescribing antibiotics. Doctors in the U.S. also have few means of 
determining to what extent their peers are misusing the resource.  
 After considering the different levels of transparency surrounding antibiotic use, one 
should not be surprised to learn that the U.S. and the Netherlands have very different levels of 
antibiotic use. Indeed, just as common pool resource theory predicts, in the U.S., where 
individual doctors can use a common-pool resource with relative privacy and without detailed 
knowledge of their counterparts actions,  the common-pool resource is being consumed in an 
unsustainable way. It is estimated that the United States should cut antibiotics prescriptions by as 
much as ninety-five percent.159 At the same time, the Netherlands has reported sustainable levels 
of antibiotic use for more than fifteen years.  
 It should be noted that the U.S. and the Netherlands also have different approaches to 
quarantine. In the U.S., quarantine regulations are written by the states, and there is a great 
disparity between the strictness of state regulations. On the other hand, the Netherlands 
quarantine laws are uniform across the nation  and the Netherlands has some of the strictest 
quarantine regulations in the world concerning antibiotic resistant infection. Strict quarantine and 
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isolation help the Netherlands to limit the negative effects that antibiotics have upon the local 
community of bacteria. If an infection is isolated, antibiotic use may still cause that infection to 
become antibiotic resistant. However, as long as the infection is killed off entirely, its resistance 
to antibiotics will not spread to the community gene pool and negatively affect other patients. In 
other words, to the extent to which an infection is kept in isolation, the use of antibiotics on that 
infection will not affect the common-pool resource. The Netherlands aggressive quarantine 
regulations is one of the two reasons cited by the Working Party on Infection Control as the 
cause of the successful containment of antibiotic resistance in the Netherlands.   
 Figure 3 shows a comparison between the institutions in the U.S. and the Netherlands. 
Figure 3 is a summary of several of the key differences between the institutional approaches 
these countries take concerning antibiotic resistance. For example, the figure show that the U.S. 
allows antibiotics to be given to animals, while the Netherlands restricts the types of antibiotics 
which can be given to animals. This figure illustrates the claim that the U.S. has many of the 
conditions associated with a tragedy of the commons, while the Netherlands has adopted several 
of the recommended design principles for institutions tasked with the protections of a common-
pool resource. 
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Policy Recommendations  
 Because antibiotic resistance is such a complex and multifaceted common-pool resource, 
and because it affects everyone, the primary organization to charged with combating increasing 
resistance should be the government. The Dutch government is an excellent example of how 
governments can address the threat antibiotic resistance poses to society. The U.S Department of 
Homeland Security, the CIA, IDSA, WHO, CDC, and ASM all agree that antibiotic resistance is 
a threat to national security in the U.S.160 Because antibiotic resistance is a national security 
threat, which will affect millions of lives, governments should pursue an active role in combating 
the threat. While some hospitals may find it worthwhile to combat antibiotic resistance 
individually, we cannot take the risk that other hospitals will not. Also, there is little individual 
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incentive for small private practices and farmers raising livestock to avoid misuse of antibiotics. 
Therefore, the U.S. government and governments like it need to take steps to protect the genetic 
makeup of infectious bacteria populations in a way that prevents or slows the increase in 
antibiotic resistance. 
 Common-pool resource management theory says that organizations can alter incentives in 
such a way that what is best for each individual is also best for the community as whole. This is 
done by first determining what the replenishment rate of the resource is. That information will 
help a society identify the maximum sustainable withdrawal rate. Then, the society should 
equitably allot rights of withdrawal so that the sum of all these is less than the maximum 
sustainable withdrawal rate. Some type of institution should be created to monitor withdrawal 
and impose graduated sanctions on those who withdrawal more than their allotment. The more 
transparent an individual's actions are, the more likely individuals are to comply with the 
established rules. Finally, it is best when the institution is made up of the people who are using 
the resource and those people have the power to democratically change the rules so that 
institution can adapt to changes in the resource or its users. 
 The Infectious Disease Society of America (IDSA) recommends that the U.S. create a 
Federal Office of Antimicrobial Resistance.161 The purpose of this office would be to coordinate 
the efforts of an interagency task force to implement the CDC's proposed action plan.162 Such an 
agency could also  impose restrictions on antibiotic use. Restrictions on antibiotic use combined 
with a high level of monitoring, an important component of the CDC's action plan, could 
drastically reduce over prescription rates in the United States.  
 Determining the replenishment rate of a common-pool resource can be difficult. In the 
case of antibiotic resistance, the replenishment rate can be considered the rate at which new 
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antibiotics, those to which infectious bacteria do not have resistance, are being developed. Once 
the proposed Federal Office of Antimicrobial Resistance determined the rate at which new 
antibiotics are being produced, it would have a sense of how stringently it will need to regulate 
use of the antibiotics currently available. The slower the development of new antibiotics, the 
lower the sustainable use rate of antibiotics will be.  
 In the Netherlands, antibiotics are still given to every patient who needs them. Doctors 
are required to use tests and cultures to prove the patient has a legitimate need and the proposed 
prescription is the appropriate one. Ideally, this is all that will need to be done in the United 
States. If it is true that close to ninety-five percent of antibiotic prescriptions in the U.S. are 
unnecessary, then simply requiring that doctors prove their patient needs the antibiotic being 
prescribed could reduce antibiotic use to sustainable levels. However, if the supply of new 
antibiotics continues to decrease, there may eventually be a day when antibiotics need to be 
saved for cases of life threatening infection. Either way, it seems logical for the appropriation of 
antibiotics to be on a level of need basis, with the newest and most potent antibiotics being 
reserved for the most resistant and/or life threatening cases.  
 The requirement that Dutch hospitals hire an infection control team has proven to be a 
successful policy and one the U.S. government should consider adopting. An infection control 
team does not work for an individual patient, and therefore, they are further separated from the 
individual incentive to overuse antibiotics. These committees work for the government, and as 
public health workers, they are well positioned to act in a way that is collectively rational. 
However, these workers are also working on the frontlines, in the hospital wards. They are 
helping doctors determine the correct prescription, monitoring antibiotic use, and reporting on 
levels of antibiotic resistant infection. To some extent, these committees accomplish what 
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common-pool resource theory recommends when it advises that those using the resource should 
also be the ones monitoring resource use and making recommendation for change in the 
institutional rules.  
 Finally, the U.S. should follow in the Netherland's footsteps and mandate aggressive 
quarantine laws. Dutch microbiologists cite strict quarantine and isolation as a key strategy for 
limiting the negative effect antibiotic use has upon the local community of bacteria. If an 
antibiotic resistant infection is isolated and killed, its resistance to antibiotics will not spread to 
the community gene pool and negatively affect other patients. To the extent to which an infection 
is kept in isolation, the use of antibiotics on that infection will not contribute to an increase in the 
likelihood of antibiotic resistance in future infections. Making hospitals legally and fiscally 
responsible for antibiotic resistant infections acquired at their hospital would be an excellent 
form of graduated sanctions for hospitals which disregard quarantine laws. If hospitals lose 
control of an infection, they would be required to compensate everyone in their hospital to whom 
the infection spread. This would give hospitals considerable fiscal incentive to use strict 
quarantine procedures. The more threatening the infection, the greater the incentive to control it 
would be. The cost and benefit analysis performed in the Dutch hospital Amphia proves that 
strict quarantine and intensive monitoring of antibiotic use can save both lives and money. The 
greatest source of antibiotic resistant infections in the Netherlands is patients being transferred 
into the country from foreign hospitals. Because the U.S. is much larger country, it can be 
assumed that a much smaller percentage of patients in the U.S. were transferred into the country 
from foreign institutions. If this is true, then a search and destroy policy in the United States 
could be even more successful than the practice was found to be in the Netherlands. 
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A Call to Action 
 If antibiotic resistance continues to spread, countries such as the U.S. could face  a tragic 
scenario in which treatable bacterial infections become untreatable, as they were before the 
invention of penicillin. Societies cannot continue to overuse antibiotics, as they have done with 
penicillin. The supply of new antibiotics is dwindling and the number of antibiotic resistant 
bacteria continues to grow. Therefore, societies need use the antibiotics they have in a 
sustainable way so that the growth of antibiotics resistance does not outpace the discovery of 
new antibiotics. Antibiotic resistance is a complex and multifaceted problem.163 However, one 
can find guidance for combating this problem by looking at the theory developed around the 
governance of the commons. This theory shows that incentives must be altered so that individual 
incentives align with what is best for the community as a whole.164 While some hospitals may 
find it worthwhile to combat antibiotic resistance individually, and this is the ideal situation, 
societies in which antibiotic resistance is growing rapidly cannot take the risk that some hospitals 
will not use antibiotics responsibly. Therefore, governments need to take steps to protect the 
genetic makeup of infectious bacteria populations in a way that prevents or slows the increase in 
antibiotic resistance. These institutions can prevent a tragedy of the commons by following the 
guidelines provided by Eleanor Ostrom and other common-pool resource governance experts. 
These experts tell us that individuals can come together to keep antibiotic resistance from 
spreading through collective action to create rules of use, implement sanctions, and monitor in a 
way which gives doctors and others sufficient incentive to use antibiotics in a collectively 
sustainable manner.  
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